Cogstate Financial Results and Investor Webcast Notification

Cogstate Ltd (ASX:CGS) advises that it will release its Appendix 4D and Financial Report for the half-year ended 31 December 2020 on Thursday 25 February 2021.

On that same day, investors are invited to join Cogstate CEO, Brad O'Connor, for a live webcast and Q&A presenting the half-year financial results at 10:30am, Australian eastern daylight savings time.

Investors can register via the following weblink to join the live event or receive the recording if unable to attend:
https://bit.ly/3dji0CN

This announcement was authorised for release by Cogstate CEO, Brad O'Connor.

About Cogstate
Cogstate Ltd (ASX:CGS) is a leading neuroscience technology company optimizing brain health assessments to advance the development of new medicines and to enable earlier clinical insights in healthcare. Cogstate technologies provide rapid, reliable and highly sensitive computerized cognitive tests across a growing list of domains and support electronic clinical outcome assessment (eCOA) solutions to replace costly and error-prone paper assessments with real-time data capture. The company's clinical trials solutions include quality assurance services for study endpoints that combine innovative operational approaches, advanced analytics and scientific consulting. For over 20 years, Cogstate has proudly supported the leading-edge research needs of biopharmaceutical companies and academic institutions and the clinical care needs of physicians and patients around the world. Cogstate and pharmaceutical company, Eisai, recently established a global exclusive partnership to develop and market cognitive assessment tools for individuals and doctors around the world.

For more information about Cogstate, please visit www.cogstate.com

For further information contact:
Brad O'Connor, Chief Executive Officer, boconnor@cogstate.com